RALEIGH, North Carolina, March 4 /PRNewswire/ --
DARA BioSciences(TM) (Nasdaq: DARA) announced today the appointment of David J. Drutz, MD to the Board of Directors. Dr. Drutz was appointed to fill a Board vacancy and will serve on the Company's Compensation Committee as well as Corporate Governance and Nominating Committee. The appointment was effective February 26, 2008.
Richard Franco, Sr., DARA's Board Chairman, commented, "It is a pleasure to announce David's appointment. Considering his varied background and successful experiences, David will add another positive dimension to our Board."
Dr. Drutz's background includes senior executive positions in the pharma and biotech industries. He is currently President of Pacific Biopharma Associates, LLC and a General Partner with Pacific Rim Ventures Company, Ltd. He serves as a director in both the public and private sectors, is a member of several scientific advisory boards, and holds a certificate of director education from the National Association of Corporate Directors.
About DARA BioSciences, Inc.
DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including type 2 diabetes, dyslipidemia and dermatological disorders. DARA has licensed promising drug development candidates from Kirin Pharmaceuticals of Japan, Bayer Pharmaceuticals Corporation, Massachusetts General Hospital and Nuada LLC.
For more information please contact the Company at +1-919-872-5578 or visit our web site at www.darabio.com.
All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Those factors include risks and uncertainties relating to the company's ability to develop and bring new products to market as anticipated, the current regulatory environment in which the company develops and sells its products, the market acceptance of those products, dependence on partner, successful performance under collaborative and other commercial agreements, competition, the strength of DARA's intellectual property, the intellectual property of others and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission. Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.
Web site: http://www.darabio.com
John C. Thomas, Jr., Chief Financial Officer, +1-919-872-5578; or Lynn H. Morris, Sr. Manager Investor Relations & Corporate Operations, +1-919-872-5578, both of DARA BioSciences, Inc.
